Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Panagiotis Konstantinopoulos, Ph.D., M.D.

Co-Author

This page shows the publications co-authored by Panagiotis Konstantinopoulos and Alan D'Andrea.
Connection Strength

3.690
  1. Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer. Cancer Discov. 2015 Nov; 5(11):1137-54.
    View in: PubMed
    Score: 0.653
  2. A Replication stress biomarker is associated with response to gemcitabine versus combined gemcitabine and ATR inhibitor therapy in ovarian cancer. Nat Commun. 2021 09 22; 12(1):5574.
    View in: PubMed
    Score: 0.246
  3. Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol. 2020 07; 21(7):957-968.
    View in: PubMed
    Score: 0.226
  4. Author Correction: Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer. Nat Commun. 2020 05 18; 11(1):2543.
    View in: PubMed
    Score: 0.224
  5. Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer. Nat Commun. 2020 03 19; 11(1):1459.
    View in: PubMed
    Score: 0.222
  6. Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma. JAMA Oncol. 2019 Aug 01; 5(8):1141-1149.
    View in: PubMed
    Score: 0.212
  7. Olaparib and a-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial. Lancet Oncol. 2019 04; 20(4):570-580.
    View in: PubMed
    Score: 0.207
  8. Prediction of DNA Repair Inhibitor Response in Short-Term Patient-Derived Ovarian Cancer Organoids. Cancer Discov. 2018 11; 8(11):1404-1421.
    View in: PubMed
    Score: 0.200
  9. EZH2 promotes degradation of stalled replication forks by recruiting MUS81 through histone H3 trimethylation. Nat Cell Biol. 2017 Nov; 19(11):1371-1378.
    View in: PubMed
    Score: 0.188
  10. DNA Damage and Repair Biomarkers of Immunotherapy Response. Cancer Discov. 2017 07; 7(7):675-693.
    View in: PubMed
    Score: 0.183
  11. Clear cell ovarian cancers with microsatellite instability: A unique subset of ovarian cancers with increased tumor-infiltrating lymphocytes and PD-1/PD-L1 expression. Oncoimmunology. 2017; 6(2):e1277308.
    View in: PubMed
    Score: 0.178
  12. Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer. Oncotarget. 2016 Mar 22; 7(12):13587-98.
    View in: PubMed
    Score: 0.168
  13. Nucleotide excision repair (NER) alterations as evolving biomarkers and therapeutic targets in epithelial cancers. Oncoscience. 2015; 2(12):942-3.
    View in: PubMed
    Score: 0.166
  14. Association of Polymerase e-Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1. JAMA Oncol. 2015 Dec; 1(9):1319-23.
    View in: PubMed
    Score: 0.165
  15. Homologous-recombination-deficient tumours are dependent on Pol?-mediated repair. Nature. 2015 Feb 12; 518(7538):258-62.
    View in: PubMed
    Score: 0.156
  16. A unique subset of epithelial ovarian cancers with platinum sensitivity and PARP inhibitor resistance. Cancer Res. 2015 Feb 15; 75(4):628-34.
    View in: PubMed
    Score: 0.155
  17. The CHK1 Inhibitor Prexasertib Exhibits Monotherapy Activity in High-Grade Serous Ovarian Cancer Models and Sensitizes to PARP Inhibition. Clin Cancer Res. 2019 10 15; 25(20):6127-6140.
    View in: PubMed
    Score: 0.053
  18. DYNLL1 binds to MRE11 to limit DNA end resection in BRCA1-deficient cells. Nature. 2018 11; 563(7732):522-526.
    View in: PubMed
    Score: 0.050
  19. MicroRNAs down-regulate homologous recombination in the G1 phase of cycling cells to maintain genomic stability. Elife. 2014 Apr 30; 3:e02445.
    View in: PubMed
    Score: 0.037
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.